{"id":5646,"date":"2007-07-06T07:44:00","date_gmt":"2007-07-06T07:44:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=5646"},"modified":"2022-04-01T12:12:43","modified_gmt":"2022-04-01T12:12:43","slug":"granulocytapheresis-in-inflammatory-bowel-disease-efficacy-of-an-induction-plus-maintenance-sessions-protocol-at-32-weeks","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/de\/professional\/scientific-corner\/granulocytapheresis-in-inflammatory-bowel-disease-efficacy-of-an-induction-plus-maintenance-sessions-protocol-at-32-weeks\/","title":{"rendered":"Granulocytapheresis in inflammatory bowel disease Efficacy of an induction plus maintenance sessions protocol at 32 weeks"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Fern%C3%A1ndez+P%C3%A9rez+FJ&amp;cauthor_id=18271660\">F J Fern\u00e1ndez P\u00e9rez<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/18271660\/#affiliation-1\">1<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Rodr%C3%ADguez+F&amp;cauthor_id=18271660\">F Rodr\u00edguez<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=de+Sola+C&amp;cauthor_id=18271660\">C de Sola<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Fern%C3%A1ndez+Moreno+N&amp;cauthor_id=18271660\">N Fern\u00e1ndez Moreno<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Vera+F&amp;cauthor_id=18271660\">F Vera<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Rivera+R&amp;cauthor_id=18271660\">R Rivera<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=S%C3%A1nchez+Cantos+A&amp;cauthor_id=18271660\">A S\u00e1nchez Cantos<\/a>, Rev Esp Enferm Dig. 2007 Nov;99(11):628-35.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><strong>Introduction:\u00a0<\/strong>Granulocytapheresis (GCAP) eliminates activated granulocytes-monocytes from peripheral blood, thus modifying the circulating pool of leukocytes and reducing intestinal inflammation. <strong>Objective:\u00a0<\/strong>To evaluate the efficacy of GCAP in inflammatory bowel disease (IBD) using an induction and maintenance protocol. <strong>Material and method:\u00a0<\/strong>A retrospective study including patients with active corticosteroid-dependent or refractory IBD. Induction included 5 sessions in ulcerative colitis (UC) and 7 sessions in Crohn&#8217;s disease (CD); one monthly session was used thereafter until week 32. Clinical activity indices and use of corticosteroids were monitored. <strong>Results:\u00a0<\/strong>Eighteen patients were included (10 with UC, 8 with CD), 10 of them dependent on and 8 refractory to corticosteroids. Fourteen of them were refractory and a further 4 were intolerant to immunosuppressants (IS). Induction was not completed in 2 UC (severe relapses) and 1 CD (side-effects) patients. One UC and 3 CD patients withdrew during maintenance. Among patients who completed induction, response or remission was achieved in 87.5% of UC cases (2 and 5 patients) and 71.4% of CD cases (1 and 4 patients), respectively. At week 32 response-remission rates reached 75% in CU (3 and 3 patients) and 42.8% in CD (1 and 2 patients) cases, respectively. Corticosteroid withdrawal was possible in 14.2% of CD and in 62.5% of UC patients (25% in remission and 37.5% with response). There were two major side effects (thrombophlebitis and syncope). No colectomies were performed for UC patients who completed GCAP induction after a mean follow-up of 97.6 weeks (range: 72-128). <strong>Conclusions<\/strong>: Both UC and CD respond well to GCAP induction. At 32 weeks UC patients maintain similar response-remission rates (87.5 vs. 75%), whereas almost one-third of CD patients lose response. Granulocytapheresis is an alternative, steroid-sparing treatment modality to induce and maintain remission in UC, while good patient selection and a maintenance protocol not well defined yet are needed for CD.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/18271660\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/18271660\/<\/a><\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"http:\/\/www.grupoaran.com\/mrmUpdate\/lecturaPDFfromXML.asp?IdArt=459857&amp;TO=RVN&amp;Eng=1\" target=\"_blank\" rel=\"noreferrer noopener\">)http:\/\/www.grupoaran.com\/mrmUpdate\/lecturaPDFfromXML.asp?IdArt=459857&amp;TO=RVN&amp;Eng=1<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>F J Fern\u00e1ndez P\u00e9rez&nbsp;1,&nbsp;F Rodr\u00edguez,&nbsp;C de Sola,&nbsp;N Fern\u00e1ndez Moreno,&nbsp;F Vera,&nbsp;R Rivera,&nbsp;A S\u00e1nchez Cantos, Rev Esp Enferm Dig. 2007 Nov;99(11):628-35. Introduction:\u00a0Granulocytapheresis (GCAP) eliminates activated granulocytes-monocytes from peripheral blood, thus modifying the circulating pool of leukocytes and reducing intestinal inflammation. Objective:\u00a0To evaluate the efficacy of GCAP in inflammatory bowel disease (IBD) using an induction and maintenance protocol. [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[147,330,159,314,91,523,55,135,306],"class_list":["post-5646","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-clinical-remission","scientific_tags-clinical-trial","scientific_tags-crohns-disease","scientific_tags-digestive","scientific_tags-maintenance","scientific_tags-steroid-tapering","scientific_tags-steroid-dependent","scientific_tags-steroid-refractory","scientific_tags-ulcerative-colitis"],"acf":{"sc_authors":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Granulocytapheresis in inflammatory bowel disease Efficacy of an induction plus maintenance sessions protocol at 32 weeks - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocytapheresis-in-inflammatory-bowel-disease-efficacy-of-an-induction-plus-maintenance-sessions-protocol-at-32-weeks\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Granulocytapheresis in inflammatory bowel disease Efficacy of an induction plus maintenance sessions protocol at 32 weeks - Adacyte\" \/>\n<meta property=\"og:description\" content=\"F J Fern\u00e1ndez P\u00e9rez&nbsp;1,&nbsp;F Rodr\u00edguez,&nbsp;C de Sola,&nbsp;N Fern\u00e1ndez Moreno,&nbsp;F Vera,&nbsp;R Rivera,&nbsp;A S\u00e1nchez Cantos, Rev Esp Enferm Dig. 2007 Nov;99(11):628-35. Introduction:\u00a0Granulocytapheresis (GCAP) eliminates activated granulocytes-monocytes from peripheral blood, thus modifying the circulating pool of leukocytes and reducing intestinal inflammation. Objective:\u00a0To evaluate the efficacy of GCAP in inflammatory bowel disease (IBD) using an induction and maintenance protocol. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocytapheresis-in-inflammatory-bowel-disease-efficacy-of-an-induction-plus-maintenance-sessions-protocol-at-32-weeks\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-01T12:12:43+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocytapheresis-in-inflammatory-bowel-disease-efficacy-of-an-induction-plus-maintenance-sessions-protocol-at-32-weeks\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocytapheresis-in-inflammatory-bowel-disease-efficacy-of-an-induction-plus-maintenance-sessions-protocol-at-32-weeks\/\",\"name\":\"Granulocytapheresis in inflammatory bowel disease Efficacy of an induction plus maintenance sessions protocol at 32 weeks - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2007-07-06T07:44:00+00:00\",\"dateModified\":\"2022-04-01T12:12:43+00:00\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocytapheresis-in-inflammatory-bowel-disease-efficacy-of-an-induction-plus-maintenance-sessions-protocol-at-32-weeks\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Granulocytapheresis in inflammatory bowel disease Efficacy of an induction plus maintenance sessions protocol at 32 weeks - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocytapheresis-in-inflammatory-bowel-disease-efficacy-of-an-induction-plus-maintenance-sessions-protocol-at-32-weeks\/","og_locale":"de_DE","og_type":"article","og_title":"Granulocytapheresis in inflammatory bowel disease Efficacy of an induction plus maintenance sessions protocol at 32 weeks - Adacyte","og_description":"F J Fern\u00e1ndez P\u00e9rez&nbsp;1,&nbsp;F Rodr\u00edguez,&nbsp;C de Sola,&nbsp;N Fern\u00e1ndez Moreno,&nbsp;F Vera,&nbsp;R Rivera,&nbsp;A S\u00e1nchez Cantos, Rev Esp Enferm Dig. 2007 Nov;99(11):628-35. Introduction:\u00a0Granulocytapheresis (GCAP) eliminates activated granulocytes-monocytes from peripheral blood, thus modifying the circulating pool of leukocytes and reducing intestinal inflammation. Objective:\u00a0To evaluate the efficacy of GCAP in inflammatory bowel disease (IBD) using an induction and maintenance protocol. [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocytapheresis-in-inflammatory-bowel-disease-efficacy-of-an-induction-plus-maintenance-sessions-protocol-at-32-weeks\/","og_site_name":"Adacyte","article_modified_time":"2022-04-01T12:12:43+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocytapheresis-in-inflammatory-bowel-disease-efficacy-of-an-induction-plus-maintenance-sessions-protocol-at-32-weeks\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocytapheresis-in-inflammatory-bowel-disease-efficacy-of-an-induction-plus-maintenance-sessions-protocol-at-32-weeks\/","name":"Granulocytapheresis in inflammatory bowel disease Efficacy of an induction plus maintenance sessions protocol at 32 weeks - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2007-07-06T07:44:00+00:00","dateModified":"2022-04-01T12:12:43+00:00","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocytapheresis-in-inflammatory-bowel-disease-efficacy-of-an-induction-plus-maintenance-sessions-protocol-at-32-weeks\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific-corner\/5646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/media?parent=5646"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific_tags?post=5646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}